Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation ModelBusiness Wire • 09/21/26
This Digital Realty Trust Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayBenzinga • 09/21/26
Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength?Zacks Investment Research • 09/18/26
Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook24/7 Wall Street • 09/17/26
Tempus AI, Inc. (TEM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare InnovationBusiness Wire • 09/11/26
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in CardiologyBusiness Wire • 09/09/26
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceBusiness Wire • 09/04/26
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGsBusiness Wire • 08/24/26
A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to KnowThe Motley Fool • 08/22/26
Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a TradeThe Motley Fool • 08/22/26
Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should KnowThe Motley Fool • 08/22/26
What to Know About the CFO of Tempus AI's Latest Insider Transaction FilingThe Motley Fool • 08/22/26
Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What HappenedThe Motley Fool • 08/22/26
Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter.The Motley Fool • 08/22/26